Lupin Launches Generic Version Of Oracea Capsules In U.S.

The company said it has launched the medication, indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea, following approval from the U.S. FDA.

PTI

Lupin said it has launched the medication, indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea following FDA's approval. (Image Source: Freepik)

Drug maker Lupin on Wednesday said it has launched the generic version of Oracea capsules in the U.S. market. The company said it has launched the medication, indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea, following approval from the U.S. Food and Drug Administration.

As per the IQVIA MAT data, Doxycycline capsules (Oracea) had estimated annual sales of $128 million in the U.S.

Shares of the company were trading 0.77% up at Rs 1,617.35 apiece on Bombay Stock Exchange.

Watch LIVE TV, Get Stock Market Updates, Top Business, IPO and Latest News on NDTV Profit. Feel free to Add NDTV Profit as trusted source on Google.
GET REGULAR UPDATES
Add us to your Preferences
Set as your preferred source on Google